Impel - Pharmaceuticals Proprietary Precision Olfactory Delivery (POD) Technology

Impel Pharmaceuticals has developed a proprietary drug delivery technology system that targets the vascular-rich upper nasal space,¹ with multiple clinical trials suggesting rapid absorption and consistent drug bioavailability with ease of use in mind for a patient, provider or caregiver. Impel Pharmaceuticals proprietary Precision Olfactory Delivery (POD^®) technology has the potential to lead to injection-like bioavailability, which may improve clinical outcomes non-invasively.

Most popular related searches

drug delivery technology

nasal delivery

nasal cavity

clinical outcome

therapeutic potential

drug delivery

clinical trial

drug delivery system

pharmaceutical development

Impel Pharmaceuticals is the first company to attempt to harness the benefits of delivery to the upper nasal space to improve the therapeutic potential of medicines for people suffering from diseases with high unmet medical needs.

Unlike traditional nasal delivery systems, such as pumps, that predominantly deliver medicine to the lower nasal cavity and suffer from high variability and low overall absorption, our therapies are designed to achieve rapid absorption with consistent and predictable doses.²

Impel - Pharmaceuticals Proprietary Precision Olfactory Delivery (POD) Technology

We Believe